Updated on 31 July 2014
Singapore: US based Mystic Pharmaceuticals has developed a drug delivery device that enables patients to self administer drugs and biologics formulated as powders for systemic nasal, nose-to-brain, ophthalmic, sublingual and buccal routes of administration.
Mystic Pharmaceuticals has recieved a Notice of Allowance from the United States Patent Office for its powder dispending device.
"Drugs and biologics formulated, packaged and delivered as powders offer tremendous benefits for product stability and can eliminate the need for cold chain management. Our technology provides precision delivery of prescription medications utilizing low cost, mono-dose or multi-dose dispensers without the expense and complexity of volatile propellants," said Mr Timothy Sullivan, president and CEO, Mystic.
Innovation in delivery platform technologies and product integration services enable pharmaceutical and biotech manufacturers to develop drug/device combination products that can extend or establish market exclusivity and competitive differentiation for new or existing drugs and biologics.